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Case presentations
Patient 1. A 19-year-old woman was admitted to the University of
Utah Health Sciences Center for evaluation of proteinuria. Two months
earlier, she had noted the onset of ankle swelling and a 12-pound weight
gain. She had no history of renal disease, she did not take medications,
and she had not been exposed to toxins. No rash, arthritis, or other
systemic signs or symptoms were present.
The supine blood pressure was 110/68 mm Hg. The optic fundi were
normal. The chest was clear and the heart was normal. No organomeg-
aly was detected; 2+ pitting ankle edema was present bilaterally.
The serum creatinine was 0.8 mg/dl; BUN, 19 mg/dl; albumin, 2.1
g/liter; and C3, 134 mg/dl. Antinuclear antibody was less than 1:10.
Urinalysis showed a specific gravity of 1.016; pH, 6.6; 4+ protein; and
was negative for blood. Microscopic examination disclosed 10—12 white
blood cells with 2—3 hyaline and granular casts/high-power field. Oval
fat bodies also were present. The 24-hr urine protein excretion was 9.4
g and the creatinine clearance 115 mllmin/1 .73 m2. Ultrasound exami-
nation revealed normal kidneys with no evidence of obstruction.
A percutaneous renal biopsy was performed. Light microscopy
showed that the glomeruli were normal or had minimal changes in the
mesangium (Fig. IA). Immunofluorescence microscopy revealed 3+
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diffuse granular 1gM and C3 confined to the mesangium of all glomeruli
(Fig. 1B). Ultrastructural examination showed effacement of podo-
cytes, but no electron-dense deposits (Fig. 1C). Based on the renal
biopsy, a diagnosis of minimal-change disease was made.
The presence of symptomatic nephrotic syndrome prompted treat-
ment with oral prednisone, 60 mg/day for 2 weeks; the dose was then
changed to 120 mg on alternate days for an additional 6 weeks. The
prednisone was tapered and discontinued over a subsequent 4-week
period. By the eighth week of oral prednisone therapy, protein excre-
tion was 9.4 g/24 hours. Two months later, proteinuria was unchanged
and an 8-week course of oral cyclophosphamide, 2 mg/kg, was started.
By the eighth week of cyclophosphamide therapy, protein excretion
had decreased to 2.4 g/24 hours; 4 weeks after the cyclophosphamide
was discontinued, the proteinuria had increased to 8.9 g/24 hours.
Patient 2. A 26-year-old man was referred to the nephrology clinic at
the University of Utah Health Sciences Center. Nine months earlier, he
had developed weight gain, ankle edema, and symptomatic orthostatic
hypotension. Urinalysis showed 4+ proteinuria and 2+ blood; the urine
sediment contained 10—15 red blood cells, 3—5 white blood cells, and 1—2
granular or hyaline casts/high-power field, Oval fat bodies were readily
identified. The serum creatinine was 2.1 mg/dl and the 24-hour protein
excretion was 18.4 g; creatinine clearance was 66 mI/mm/I .73 m2. The
serum albumin was 1.6 g/liter. The patient was admitted to a local
hospital, where an open renal biopsy was performed. He was treated
with saline and albumin infusions and was given I g of intravenous
methylprednisolone daily for 3 days. Orthostatic hypotension im-
proved. Oral prednisone, 60 mg/day, was continued for an additional 8
weeks, after which the drug was tapered and discontinued over 6
weeks. Six weeks after institution of steroid therapy, protein excretion
was 3.4 g/24 hours and, when the prednisone was discontinued, protein
excretion was 0.18 g/24 hours. The patient did well until 3 weeks prior
to the current visit, when ankle edema reappeared. Physical examina-
tion showed a supine blood pressure of 132/68 mm Hg with a sitting
blood pressure of 118/60 mm Hg. The pulse was 94 beats/mm and
regular, and the chest examination was normal. The only positive
finding was 3+ pitting edema to the knees.
Urinalysis again revealed 4+ protein and 2+ blood, and the urine
sediment contained numerous red and white cells/high-power field as
well as granular casts and oval fat bodies. The serum creatinine was 1.8
mg/dl and the albumin, 2.8 g/liter. Review of the renal biopsy from the
local hospital showed that generalized and diffuse mesangial hypercel-
lularity was present in all of the glomeruli on light microscopy (Fig. 2A).
Immunofluorescence microscopy revealed 3 + diffuse granular 1gM and
C3, with trace IgG in the mesangium of all glomeruli (Fig. 2B).
Ultrastructural examination showed numerous paramesangial electron-
dense deposits and effacement of podocytes (Fig. 2C).
The patient was retreated with an 8-week course of prednisone, 60
mg/day. After 8 weeks of prednisone, the 24-hour protein excretion was
12.6 g. After the prednisone was tapered and discontinued, an 8-week
course of cyclophosphamide, 2 mg/kg, was started. At the end of this
period, the proteinuria had decreased to 0.4 g/24 hours. The patient
remained in remission for 10 months, at which time heavy proteinuria
recurred. After 8 weeks of a second course of oral cyclophosphamide,
the urine protein excretion was 14.3 g/24 hours. One year later, the
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Discussion
DR. WAYNE A. BORDER (Chief, Division of Nephrology,
University of Utah Health Sciences Center, and Professor of
Medicine, University of Utah School of Medicine, Salt Lake
City, Utah): The relationship among minimal-change disease,
mesangial proliferative glomerulonephritis, and focal and seg-
mental glomerulosclerosis (focal sclerosis) is a topic guaranteed
to stimulate controversy among nephrologists and renal pathol-
ogists. One popular hypothesis is that these histologic forms of
glomerulonephritis are not separate entities but simply repre-
sent a spectrum of disease that begins with minimal changes and
ends in focal sclerosis. An alternative view, which I support, is
that the three are separate entities but that they have certain
overlapping features with regard to microscopic appearance
and response to therapy. The two cases presented here were
selected to demonstrate this overlap. In the first patient, light
microscopy showed only minimal changes, but the mesangium
contained 1gM and C3 deposits. Some would consider the latter
finding incompatible with a diagnosis of minimal-change dis-
ease. The response to prednisone treatment was disappointing
and consistent with the idea that the patient did not have
minimal-change disease. The second patient clearly had mesan-
gial proliferation along with 1gM and C3 deposits. Steroid
treatment induced a complete remission of his proteinuria. On
relapse, he failed to respond to a second course of prednisone
therapy but did respond to cyclophosphamide. The patient later
relapsed again and became refractory to cyclophosphamide
treatment. A second renal biopsy showed worsening of the
mesangial proliferative changes, and segmental sclerosis was
present. I believe the correct diagnosis in both these patients is
mesangial proliferative glomerulonephritis and that both pa-
tients demonstrate the early and late phases of an entity called
"1gM mesangial nephropathy" [1]. To provide evidence for this
assertion, I would like to review the new experimental infor-
mation about the glomerular mesangium and the combined
experimental and clinical data from humans with these three
glomerular disorders.
The glomerular mesan glum
FIg. 1. Renal biopsy from Patient 1. A Glomerulus with minimal
mesangial abnormalities (periodic acid-Schiff x 500). B Diffuse mesan-
gial deposits of 1gM (x 500). C Electron micrograph showing efface-
ment of the epithelial foot processes (x 10,000).
patient had persistent nephrotic syndrome, and the creatinine was 2.2
mg/dl. A repeated renal biopsy showed progression of the proliferative
changes, with 3 of 12 glomeruli showing segmental sclerosis (Fig. 3).
Both 1gM and C3 were still present in heavy quantities in the mesan-
gium.
Recent research has indicated a central role for the mesan-
gium in the normal function of the glomerulus and in the
pathology of glomerular disease. The most common form of
glomerulonephritis, IgA nephropathy [2], is a mesangial dis-
ease. Other forms of mesangial proliferative glomerulonephritis
and IgA nephropathy are the most frequent causes of isolated
hematuria [3] and/or hematuria and proteinuria found in pa-
tients undergoing diagnostic renal biopsy [4, 51. Mesangial
proliferative glomerulonephritis is also a cause of the nephrotic
syndrome [6, 7]. Diabetic nephropathy has long been thought to
be a disorder of hyperglycemia with secondary thickening of the
glomerular basement membrane. Mauer and coworkers showed
that it is the volume of the mesangium as it undergoes expan-
sion, rather than the thickness of the glomerular basement
membrane, that correlates best with the development of pro-
teinuria, azotemia, and hypertension in diabetic patients [8]. In
experimental animals, a variety of factors including hyperfiltra-
tion [9], hypertension [10, 11], intravascular coagulation [121,
and metabolic alterations [13] have been considered responsible
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Fig. 2. First renal biopsy from Patient 2. A Glomerulus shows
diffuse mesangial proliferation (periodic acid-Schiff x 500). B
Diffuse mesangial deposits of 1gM x 500. C Electron
micrograph showing effacement of epithelial foot processes
and electron-dense deposits (arrows) adjacent to the basement
membrane (x 10,000).
Table 1. Components of the mesangiuma
Fig. 3. Second renal biopsy from Patient 2. Glomerulus showing area of
segmental sclerosis (periodic-acid Schiff X 500).
for the development of the mesangial lesion of glomeruloscle-
rosis.
The possibility that the components of the mesangium (Table
1) are central to the pathogenesis of many forms of human
glomerular disease has been recognized since 1980 [14, 15]. The
history of the mesangium began in 1933 when Zimmerman
coined the term and defined it as connective tissue lying
between the glomerular capillaries [16]. Three years later,
Kimmelstiel and Wilson published their famous paper on dia-
Intrinsic contractile cell
Resembles a vascular smooth muscle cell
Contains cytoskeletal fibrils of myosin
Possesses All and H1 receptors
Secretes matrix components
Extrinsic bone marrow-derived cell
Resembles macrophage/monocyte
Phagocytic, with Fc and C receptors
LCA positive
Subset Ia positive
Secretes matrix components?
Extraceilular matrix
Resembles glomerular basement membrane
Modulates cell proliferation
Modulates response to growth factors
a Adapted from Refs. 14, 15, 22, 23, 38—44.
betic glomerulosclerosis, which described mesangial abnormal-
ities [17]. The anatomy of the mesangium was largely unknown
until 1960, when Latta and Maunsbach published a pioneering
study using the electron microscope to describe its ultrastruc-
ture [181. In 1962 Farquhar and Palade suggested a functional
role for the mesangium [19] and described the mesangial uptake
of injected ferritin [20]. Eleven years later, Mauer and cowork-
ers produced an experimental model of a proliferative glomer-
ulonephritis confined to the mesangium [21]. The current ex-
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Fig. 4. Transmission electron-micrograph in which normal mesangial
cells have been outlined by India ink, demonstrating their complex
intracapillary location (x 5,000). (Reproduced with permission from
Lab Invest 52:453—461, 1985.)
plosion in knowledge concerning the mesangium is due in great
part to the successful growth of rat mesangial cells in culture in
1976 [22]. In 1980, Ausiello and colleagues described the
contraction of mesangial cells by angiotensin II [23]. This
discovery led to the description of the potential of the mesan-
gium as a determinant of glomerular hemodynamics [241. The
first comprehensive review of the mesangium was published in
1980 [14].
Mesangial anatomy. It always has been difficult to visualize
the structure of the mesangium because of its intracapillary
location within the glomerulus (Fig. 4). Jones developed a
technique for the scanning electron microscope that utilizes
enzymes to dissolve the glomerular basement membrane and
mesangial matrix without disturbing the complex surface rela-
tionship among the endothelial, mesangial, and epithelial cells
of the glomerulus [251. A scanning electron micrograph utilizing
the enzymatic technique shows a mesangial cell body and its
tapered foot processes as they extend and grip the fenestrated
capillary endothelium (Fig. 5). A mesangial cell network can be
seen clearly as the foot processes of adjacent mesangial cells
intertwine and surround the glomerular capillaries. The enzy-
matic dissection technique also shows that the mesangial cell
and its surrounding matrix directly connect with the plasma via
the endothelial fenestrations in the glomerular capillaries.
Mesangial function. Following the original description of the
uptake of injected colloidal carbon [26] and ferritin [20], numer-
ous studies have been conducted using a variety of tracer
materials [27, 281. These studies have been summarized by
Michael and coworkers [14], who conceptually divided the
mesangium into an afferent (uptake) and efferent (clearance)
limb. Afferent uptake depends on the blood level of a substance
and its properties, such as size, type of molecule, and charge. If
glomerular permeability is increased by administration of puro-
Fig. 5. Scanning electron-micrograph of a mesangial cell (M) and the
mesangial network that surrounds the glomerular capillaries (C) after
enzymatic digestion of the glomerular basement membrane and mesan-
gial matrix (x 6,000). (Reproduced with permission from Lab Invest
52:453—561, 1985.)
mycin aminonucleoside [27, 29, 30] or by injection of antiglo-
merular basement membrane antibodies [28, 30], the uptake of
macromolecules increases. The administration of angiotensin II
also increases mesangial uptake [31]. The removal or clearance
of macromolecules from the mesangium depends on properties
of the efferent limb that are less understood and remain contro-
versial. Most investigators now believe that only a portion of
mesangial cells are capable of phagocytosis and that the uptake
of macromolecules does not represent a phagocytic function.
Latta and Fligiel, using thorium dioxide particles of known size,
showed that the mesangium behaves as though it contains
elliptical fenestrae of 376 x 626 A [32]. Thorium dioxide
particles could easily be seen entering the endothelial fenestra-
tions and accumulating in the mesangial matrix underlying the
paramesangial basement membrane and overlying epithelial
foot processes (Fig. 6). This finding suggested that plasma
normally flows through the mesangial matrix and produces an
ultrafiltrate across the paramesangial basement membrane; this
ultrafiltrate contributes to the glomerular filtration rate [32].
Because the mesangial ultrafiltrate also must cross the glomer-
ular basement membrane before entering the urinary space,
protein would be restricted via this pathway by selectivity
factors similar to those in the glomerular capillary wall. This
discovery helped explain the clinical findings in patients with
mesangial proliferative glomerulonephritis. These patients of-
ten have electron-dense deposits along the paramesangial base-
ment membrane in a manner similar to the location of the
thorium dioxide particles. Furthermore, despite the fact that the
glomerular capillary wall appears normal, these patients can
have proteinuria and a reduction in the glomerular filtration
rate. These findings are best explained by injury occurring in
the mesangial pathway for ultrafiltration.
In the presence of proteinuria, flow may be increased through
—
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Fig. 6. Electron-micrograph following injection of thorium dioxide
particles. Note that the particles in the glomerular capillary lumen are
flowing through endothelial fenestrations (arrows) into the mesangial
matrix (x 23,000). (Reproduced with permission from Lab Invest 52:
591—598, 1985.)
the mesangium [33, 34]; this change might explain the frequent
appearance of macromolecules such as 1gM, C3, and fibrinogen
in the mesangium in a variety of disease models. Keane and Raij
rejected this interpretation; they found that material does not
deposit in the mesangium simply because proteinuria is present
[35]. Three models of proteinuria, induced by administration of
puromycin aminonucleoside, adriamycin, or by the induction of
Heymann nephritis, were studied. Mesangial uptake of tracer
particles increased only in the model induced by puromycin
aminonucleoside. Uptake did not increase in proteinuric ani-
mals that received adriamycin or that had Heymann nephritis.
Infusion of saralasin prevented increased uptake in the puro-
mycin model despite the persistence of proteinuria. Why
mesangial uptake increases in this model and not in other
models of proteinuria is unknown. What is clear is that the
uptake is not simply the nonspecific consequence of proteinuria
[15, 35].
Given the manner in which the mesangial cell network
surrounds the glomerular capillaries, it is not surprising that the
mesangial cells, through their contractile properties, can regu-
late the glomerular microcirculation [24]. Angiotensin II is the
major intrarenal hormone that regulates glomerular filtration
rate [36]. Mesangial cells possess angiotensin II receptors, and
physiologic concentrations of angiotensin II induce mesangial
cell contraction [23]. Administration of angiotensin II reduces
the glomerular ultrafiltration coefficient; this reduction likely is
mediated by mesangial cell contraction. The role of the mesan-
gium in controlling the glomerular microcirculation has been
reviewed recently [37].
Another function of mesangial cells is synthesis and mainte-
nance of the mesangial extracellular matrix [38]. Mesangial cells
in culture secrete collagen types I, III, IV, and V as well as
myosin, fibronectin, laminin, intactin, and proteoglycans [38,
39]. The mesangial extracellular matrix resembles the glomer-
ular basement membrane, and the visceral epithelial cell along
with the mesangial cell may contribute to both structures. The
rnesangial extracellular matrix (Table 1) is not a passive sub-
stance as has been proposed, but it plays an important role in
modulating the response and proliferation of cells in contact
with it. For example, it influences the functional response of
overlying cells to a variety of growth factors and also deter-
mines the structure of cells in contact with it [40]. The mesan-
gial extracellular matrix thus is not only an important compo-
nent of both the structure and function of the glomerulus, but it
also might be the key to the pathogenesis of glomerulosclerosis
[15, 38]. Analysis of the dynamic interrelationships among the
mesangial, epithelial, and possibly endothelial cells in maintain-
ing the glomerular extracellular matrix is an important area for
future research.
The combination of cell culture [41] and immunologic and
morphologic techniques has provided a clear description of the
cellular components of the mesangium (Table 1) [39, 40]. An
intrinsic contractile cell is present that resembles a vascular
smooth muscle cell. It contains cytoskeletal fibrils of myosin
and angiotensin II and histamine H1 receptors that mediate its
contractile properties [23, 42]. It also synthesizes components
of the mesangial extracellular matrix. This cell assists in regu-
lating the glomerular microcirculation. A second cell type
originates extrinsic to the glomerulus in the bone marrow [43].
Under normal circumstances this cell appears to remain dor-
mant. Stimulation, however, produces a variety of changes, and
the cell develops properties similar to those of a macrophage or
monocyte. This cell expresses the leukocyte common antigen
(LCA), a feature that distinguishes it from the intrinsic contrac-
tile cell [43]. Some of the extrinsic cells have the immune-
response gene antigen Ia on their surface; they thus are under
the genetic control of the major histocompatibility complex
[44]. This group of cells might play an important role in immune
regulation and responsiveness within the glomerulus. The abil-
ity of the extrinsic mesangial cell to secrete matrix components
has not been clarified.
Pathophysiologic potential. The study of the intrinsic and
extrinsic mesangial cells in culture has provided an understand-
ing of the mesangium and its role in the pathogenesis of
glomerulonephritis. Mesangial cells are now viewed as being in
a basal state while performing their normal physiologic and
structural functions in the glomerulus. When exposed to a
variety of stimuli—including immune complexes [45], the ter-
minal membrane-attack-complex of complement [46], and inter-
leukin- 1 [47]—mesangial cells undergo a profound transforma-
tion (Table 2), beginning with proliferation and changes in
morphology. A quantitative increase in protein and collagen
d'
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synthesis occurs, as well as in other components of the mesan-
gial matrix. Qualitative changes in the secretion of these mac-
romolecules also can occur and can alter the structure of the
extracellular matrix [38]. Stimulated mesangial cells synthesize
and release a neutral proteinase capable of degrading the
glomerular basement membrane [481. These cells also release
prostanoids [49] and reactive oxygen metabolites [50], Lovett
and coworkers recently showed that mesangial cells stimulated
by exposure to macrophage interleukin-l undergo transforma-
tion with the production of their own interleukin- 1; this change
can result in a self-sustaining cycle of stimulation [511. The
ability of the mesangium to be stimulated, undergo transforma-
tion, and then perpetuate this cycle without additional extrinsic
stimulation might be an important observation for our under-
standing of the pathogenesis of human glomerulonephritis. It
seems clear that immunologic injury can initiate glomerular
injury, but often glomerulonephritis seems to progress in the
absence of continued immunologic activity [52, 53]. Currently
there is intense interest in the possible role of interleukin-l
and/or other growth factors in the progression of glomerulone-
phritis. In a rat model of immune-complex glomerulonephritis,
levels of interleukin-l messenger RNA were two- to threefold
higher than levels in normal animals [541. Perhaps these ele-
vated levels of interleukin-l are involved in perpetuating the
glomerulonephritis in this model.
The potential of a substance such as interleukin- I to mediate
the progression of glomerulonephritis from the stage of cell
proliferation to that of sclerosis is of great theoretical impor-
tance. In this context, it is fascinating to recall that the kidney
manufactures the single most powerful, naturally occurring
inhibitor of interleukin- 1; this substance (uromodulin) is the
Tamm-Horsfall glycoprotein [55]. The possible biologic signif-
icance of the kidney producing its own inhibitor of interleukin- 1
is unknown.
The transformation of the resting mesangial cell to a stimu-
lated state in which it develops a variety of new biologic and
pathologic capabilities is of great interest. It might be similar to
the transformation of Dr. Jekyll into Mr. Hyde. As you remem-
ber, Dr. Jekyll was a kind, good man. He discovered a drug that
transformed him into a vicious, brutal creature named Mr.
Hyde. When the drug wore off, he again became Dr. Jekyll. I
believe that the resting mesangial cell can be considered the
good Dr. Jekyll, contributing to the health and normal function
of the glomerulus. Upon exposure to immunologic or other
stimuli, Dr. Jekyll becomes Mr. Hyde, and the stimulated
mesangial cell becomes capable of cell proliferation and the
release of a number of products harmful to the glomerulus. Like
the pleasant Dr. Jekyll, who became the hairy beast Mr. Hyde,
the stimulated mesangial cells also undergo structural transfor-
mation: an increase in cell number and general expansion of the
mesangial matrix. Sterzel and coworkers witnessed such a
transformation while observing mesangial cells in prolonged
culture [38]. The mesangial extracellular matrix began to accu-
mulate in nodular protrusions that resulted in so-called "hill-
ocks." These "hillocks" could be the in-vitro counterpart of
segmental mesangial sclerosis that occurs in vivo in various
forms of glomerulonephritis.
The mesangium and glomerulonephritis
With this background information on the anatomy, function,
and pathophysiologic potential of the mesangium, one can
better grasp the role of the mesangium in human glomerulone-
phritis. As I already noted, confusion and controversy surround
the interrelationships among mesangial proliferative glomerulo-
nephritis, minimal-change disease, and focal sclerosis. I believe
the key to understanding these interrelationships is the realiza-
tion that, at the beginning of mesangial injury (glomerulonephri-
tis), the resting mesangial cells appear normal or to have only
"minimal changes." After stimulation, the cells proliferate and
increase the synthesis of mesangial matrix, which can accumu-
late and cause glomerulosclerosis. Thus mesangial proliferative
glomerulonephritis is a disease with a spectrum that ranges
from normal (minimal-change), through mesangial proliferation,
to an end-point of focal sclerosis (Fig. 7). Depending on the
timing of a renal biopsy, the clinician will observe only a certain
part of the spectrum. The biopsy is a snapshot and not a moving
picture.
I believe, however, that mesangial proliferative glomerulone-
phritis, minimal-change disease, and idiopathic focal sclerosis
are three separate disorders. They overlap and can be confused
clinically because the morphologic alterations of minimal-change
disease appear similar to the minimal changes found in early
mesangial proliferative glomerulonephritis, and because the
changes of idiopathic focal sclerosis appear similar to the
findings in the late stage of mesangial proliferative glomerulo-
nephritis (Fig. 7). I do not believe that minimal-change disease
Table 2. Transformation of mesangial cells in response to
stimulation"
Cell proliferation
Changes in cell morphology
Changes in secretory phenotype
Increased protein and collagen synthesis
Release of neutral proteinase
Secretion of prostanoids, reactive oxygen metabolites,
and interleukin- 1
Minimal-change
disease
Normal or minimal
glomerular changes
"Adapted from Refs. 15, 38—41, 45—51.
Mesangial proliferative
glomerulonephritis
'I
Normal or minimal
glomerular changes
I
Minimal glomerular Mesangial proliferation
changes
I I
No progression Focal and segmental
sclerosis
Idiopathic
focal sclerosis
I,
Normal or minimal
glomerular changes
with a few glomeruli
showing sclerosis
1
Increased
proliferation
and sclerosis
I
Focal and segmental
sclerosis
Fig. 7. Mesangial proliferative glomerulonephritis, minimal-change
disease, and idiopathic focal sclerosis are separate disorders; within
their spectrum of histologic changes, they may appear similar by light
microscopy. This fact has lead to both confusion and controversy about
the nature of these forms of glomerular disease.
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evolves to mesangial proliferative glomerulonephritis and ends
as focal sclerosis. I also believe that a separate entity, idio-
pathic focal sclerosis, begins de novo as focal sclerosis. To
provide support for this viewpoint, I would like to briefly
review what is known about the pathogenesis, natural history,
and response to therapy of each of these three conditions.
Minimal-change disease. Minimal-change disease is defined
as the presence of normal or only "minimal" changes consist-
ing of a slight increase in mesangial matrix or cellularity defined
by light microscopy [56]. Immunofluorescence usually is nega-
tive, but some authors accept small amounts of 1gM and/or C3
deposits in the mesangium. Electron microscopy reveals the
only abnormality to be effacement of the foot processes, with a
normal glomerular basement membrane and the absence of
electron-dense deposits. Several studies have described abnor-
malities in the cellular immune system of patients with minimal-
change disease, In some patients, the serum contains a soluble
product that suppresses lymphocyte function [571. Injection of
supernatant from cultures of lymphocytes from patients with
minimal-change disease into the renal arteries of rats causes
patchy effacement of glomerular epithelial foot processes and a
reduction of the glomerular charge barrier [58]. Control super-
natants from normal individuals produced no such renal struc-
tural abnormalities. Bakker and coworkers isolated peripheral-
blood mononuclear cells and stimulated them with concanava-
lin A in the presence of normal renal tissue [59]. The mononu-
clear cells from the patients with minimal-change disease re-
duced stainable glomerular polyanion in the renal tissue. This
finding occurred only sporadically in control experiments using
mononuclear cells from nephrotic patients with other diseases
or from normal subjects.
The morphologic findings in minimal-change disease and the
results of numerous studies are consistent with the hypothesis
that minimal-change disease is caused by a soluble product
(possibly produced by lymphocytes) that is toxic to the glomer-
ular epithelial cell. This toxicity results in loss of the normal
integrity of the epithelial cell and a reduction in the anionic
charge-barrier that leads to proteinuria [60]. This hypothetical
toxin also might be responsible for the multiple abnormalities
detected in cellular immunity in these patients. Using such a
disease model, one could speculate that treatment with a drug
that affects lymphocytes would be highly effective and that
chronic renal failure would not occur. In fact, we have known
for years that these are major characteristics of minimal-change
disease, characteristics confirmed by 2 large clinical studies. A
study published in 1985 described 183 children with the onset of
nephrotic syndrome between 1 and 15 years of age [61]. All the
children had minimal-change disease as defined by light micros-
copy. The patients were followed until they were between 14
and 32 years old. At followup, 31 patients were alive but
unavailable for examination. Of the remaining 152 patients who
were studied, 131 were in remission and 10 had active nephrotic
syndrome. Eleven of the patients had died, 7 due to complica-
tions of the nephrotic syndrome and 4 due to unrelated causes.
None of the patients had developed progressive renal failure.
All the patients examined were steroid responsive at the onset
of the nephrotic syndrome and remained so throughout the
course. A second study, also published in 1985, described the
outcome of minimal-change disease in adults [62]. This study
included the results of 10 reported series that described a total
of 232 patients who had been followed an average of 48 months.
With steroid treatment, 82% achieved a complete remission
(defined as less than 0.2 g of proteinuria per day); 95% re-
sponded to steroid treatment with at least a partial remission
(defined as less than 1 g of proteinuria per day). Only 2 of the
232 patients had developed progressive renal failure.
In summary, the data indicate that minimal-change disease is
a disorder affecting the visceral epithelial cell. Several lines of
indirect evidence suggest that the agent responsible for this
disorder is a soluble product, toxic to this cell, that may be
derived from lymphocytes and/or that might depress lympho-
cyte function. Large clinical studies involving adults [62] and
children [61] show that steroids induce a remission of the
nephrotic syndrome (defined as excretion of less than 1 g of
protein/24 hours in 95% or more of all patients). Finally, and
very importantly, progressive renal failure in minimal-change
disease was absent or occurred so infrequently as to be in
keeping with that found in a control population. This finding is
strong evidence against the idea that minimal-change disease
and focal sclerosis are part of the same disease spectrum.
Focal sclerosis. I already have implied that stimulation of the
mesangium can result in the development of focal and segmen-
tal glomerulosclerosis. Abundant studies also indicate that a
histologically similar picture can be produced by diverse factors
such as glomerular hypertension and hyperfiltration [9], intra-
glomerular coagulation [12], urinary refiux [63], and a genetic
predisposition [64]. Thus focal sclerosis can be secondary to a
process initiated by several factors. I believe that there is also
a separate entity, for which the cause is unknown, that can be
called "idiopathic" or "primary focal sclerosis." This is the
type of focal sclerosis that can be seen in the patient with
nephrotic syndrome who has no history of renal disease [65].
Initially only a fraction of the glomeruli in these patients show
evidence of segmental sclerosis and hyalinosis [66]. Immuno-
fluorescence microscopy shows that the areas of sclerosis
contain 1gM and C3 deposits. It is also common to see 1gM and
C3 within the mesangium of otherwise-normal-appearing gb-
meruli. Light microscopy reveals, in addition to the areas of
sclerosis, generalized effacement of foot processes consistent
with a systemic disorder. Idiopathic focal sclerosis also recurs
frequently, and occasionally rapidly, in the transplanted kid-
ney. A recent study in children found that if the native kidney
showed focal sclerosis and generalized mesangial proliferation,
the recurrence rate in the transplanted kidney was 70% [67].
Conversely, if only focal sclerosis was present, the recurrence
rate was 12%. Serial studies in transplanted kidneys have
shown that the earliest lesion arises in the visceral epithelial cell
[67], which undergoes effacement of the foot processes. This
change often precedes the development of sclerosis by several
weeks. This pattern of recurrence suggests injury to the visceral
epithelial cell [66] reminiscent of that attributed to a soluble
factor in minimal-change disease. Whereas in minimal-change
disease only podocyte effacement occurs, in focal sclerosis
epithelial cells proliferate and extracellular matrix accumulates,
thus producing sclerosis [66]. Given that the epithelial and
mesangial cells determine the metabolism of extracellular ma-
trix, it is understandable that such injury can produce sclerosis.
A second distinguishing feature between idiopathic focal scle-
rosis and minimal-change disease is that the former has a poor
response to both steroid [68] and cytotoxic drug therapy [69].
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Furthermore, idiopathic focal sclerosis frequently leads to
end-stage renal disease [67—69].
In summary, focal sclerosis is a histologic finding that can be
secondary to a variety of factors. There is also evidence for a
primary entity termed idiopathic focal sclerosis that begins with
injury to the epithelial cell. Unlike minimal-change disease, this
disorder has a low response rate to drug therapy and often leads
to progressive renal failure.
Mesangial proliferative glonierulonephritis. Mesangial prolif-
erative glomerulonephritis is easily induced immunologically in
experimental animals [70], which serve as an excellent model
for the human disease. The production of circulating immune
complexes in an experimental animal rapidly leads to mesangial
deposits of immunoglobulin and complement [71]. This is not
surprising, given that plasma flow occurs across the glomerular
mesangium and given the ease with which circulating macro-
molecular material enters and becomes localized in the mesan-
gial matrix.
It has been known for more than 25 years that the first
deposits of BSA-anti BSA immune complexes in serum sick-
ness in rabbits occur within the mesangium [71]. Thus, circu-
lating immune complexes can deposit in the mesangium; they
also may form in situ in this location. In addition to BSA, serum
sickness also has been induced in a variety of animal models by
the injection of ferritin [72], thyroglobulin [70, 73], and DNA
[74]. All these antigens produce mesangial proliferative glomer-
ulonephritis. The spectrum of histologic changes begins with
normal findings by light microscopy and the presence of immu-
noglobulin and complement detected by immunofluorescence.
With continued injection of the antigen, there is a transforma-
tion to definite mesangial proliferation with expansion of the
mesangial matrix. This transformation becomes progressively
more severe and is accompanied by segmental proliferation and
sclerosis. Studies of IgA nephropathy indicate that circulating
IgA, in the form of either immune complexes and/or polymers,
localizes in the mesangium much in the way immune complexes
deposit in the animal models. In systemic immune-complex
disorders such as lupus, the earliest deposits also are found
within the mesangium; with time, mesangial proliferative gb-
merulonephritis occurs. The ability of the early mesangial
lesion in lupus to evolve into a focal proliferative or diffuse
proliferative form is well recognized. In summary, mesangial
proliferative glomerulonephritis results from immune complex
localization within the mesangium. The earliest histologic lesion
may be segmental mesangial proliferation, which can progress
to generalized mesangial hypercellularity with matrix expansion
and ultimately to segmental or diffuse sclerosis.
Models of more selective mesangial injury also have been
described. The original model reported by Mauer and cowork-
ers involved the injection of aggregated IgG into the circulation
followed by transplantation of the kidney and administration of
anti-IgG antibody into the new host [21]. These maneuvers
resulted in an acute mesangial proliferative glomerulonephritis
with activation of complement. Yamamoto and Wilson recently
reported the use of an antibody directed to a thymocyte antigen
located on the surface of mesangial cells [75]. The effect of the
antibody administration is dose dependent, beginning with only
binding and no histologic lesions, and concluding with acute
lysis of the mésangial cells. Interestingly, mcsangial cell prolif-
eration and mesangial deposits of immunoglobulin and comple-
ment also develop in this model. Another intriguing model has
been developed by the administration of a monocbonal antibody
to an unknown component of the mesangial matrix [76]. This
antibody does not produce mesangial cell proliferation but does
cause the formation of mesangial electron-dense deposits sim-
ilar to those secondary to the deposition of circulating immune
complexes. Although immune-complex deposition causes mes-
angial proliferative glomerubonephritis, other potential mecha-
nisms should be kept in mind when considering its pathogenesis
in humans. To date no evidence of an antibody directed against
the mesangial cell or the mesangial matrix has been demon-
strated in humans, but this remains an intriguing possibility.
In experimental models of mesangial proliferative glomerulo-
nephritis, the immunoglobulin usually deposited in the mesan-
gium is IgU. The question arose as to whether the class of the
immunoglobulin might predispose to the development of focal
sclerosis. This hypothesis is based on the association in human
renal biopsies between the presence of segmental sclerosis in
areas that are also rich in 1gM and C3, as determined by
immunofluorescence microscopy. We approached this question
experimentally, using either ultraviolet or heat-treated DNA,
which acts by an unknown mechanism to elicit either an IgG or
1gM antibody response [74]. Rabbits were immunized with
either of the two DNA antigens, which produced either IgG or
1gM mesangial proliferative gbomerulonephritis. The deposition
of either immunoglobulin resulted in a generalized and diffuse
mesangial proliferative gbomerulonephritis. In advanced cases,
focal and segmental glomerulonephritis occurred; we found no
evidence of a unique role of 1gM in producing this lesion. Thus,
the development of focal sclerosis in advanced mesangial
proliferative gbomerubonephritis likely is simply a manifestation
of severe injury [74].
Mesangial proliferative glomerubonephritis is the most fre-
quent cause of glomerulonephritis in humans. The most impor-
tant form of mesangial proliferative gbomerulonephritis, IgA
nephropathy, was previously reviewed in a Nephrology Forum
[2]. I therefore will not discuss IgA nephropathy except to
emphasize that it can be responsible for isolated hematuria, for
combined hematuria and proteinuria, and for nephrotic syn-
drome. Early findings in IgA nephropathy may be only minimal
mesangial proliferation. Similar histologic and clinical findings
have been described when IgA is not present but when 1gM is
the predominant immunogbobulin [1, 6]. Other authors have
described patients in whom only C3 [77] or Clq [78] is found in
the mesangium. In these cases one must remember the possi-
bility that the immunogbobulin has been "buried" by reaction
with complement components and is therefore not detectable.
Of the non-IgA forms of mesangial proliferative gbomerulone-
phritis, that due to 1gM and C3 deposition is clinically most
important.
In 1978, Drs. Cohen, Glassock, and I described a group of
patients with nephrotic syndrome who on renal biopsy had
generalized and diffuse mesangial deposits of 1gM and C3 [6].
The term 1gM mesangial nephropathy (1gM nephropathy) was
coined to categorize these patients [61. We reported a followup
study that included additional patients in 1982 [79]. Our reports
and those by other authors describing 1gM mesangial nephrop-
athy have provoked considerable discussion and some contro-
versy because the spectrum of both the histologic and clinical
features of this disease overlaps with that of minimal-change
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disease and idiopathic focal sclerosis. As I already have indi-
cated, I believe that these are three separate entities and are
distinct in pathogenesis, natural history, and clinical response
to treatment (Fig. 7). Before addressing the controversy, I first
would like to describe the clinical features of 1gM mesangial
nephropathy.
We reviewed approximately 1300 renal biopsies performed
after 1975 and selected only those in which immunofluores-
cence microscopy showed diffuse and generalized 1gM mesan-
gial deposits [6, 791. We excluded those that showed focal
sclerosis. The medical records were reviewed, and patients also
were excluded if there was evidence of a systemic disease such
as lupus or vasculitis. From this review, 29 patients were
identified who had adequate biopsy tissue and for whom suffi-
cient clinical data were available. Of these 29 patients, 22 were
males and 7 females. Their ages ranged from 2 to 75 years. Of
the 9 pediatric patients, the mean age was 6.9 years; the mean
age for the 20 adult patients was 34.6 years. There was no
difference in presentation, progression, or response to therapy
between adults and children, so they will be considered to-
gether. In addition to diffuse deposition of 1gM, C3 deposits
were present in the mesangium of all patients. None of the
patients had IgA deposits. Light microscopy varied from dis-
closing normal glomeruli to revealing varying degrees of mesan-
gial hypercellularity and increased mesangial matrix. Electron
microscopy showed generalized foot-process effacement; mes-
angial electron-dense deposits were seen in less than 50% of the
patients. In general, a poor correlation existed between the
severity of mesangial changes by light microscopy and the
clinical manifestations. Most patients were treated with pred-
nisone, 60 mg/day, or its equivalent. In patients who did not
respond to prednisone or who relapsed, cyclophosphamide at a
dose of 1—2 mg/kg/day was utilized. The course of prednisone or
cyclophosphamide was continued for a minimum of 8 weeks.
Twenty-three of the patients had heavy proteinuria (greater
than 3 g/day); 9 of these also had microscopic hematuria. The
remaining 6 patients had isolated hematuria without protein-
uria. Of the 23 patients with proteinuria, 19 were treated with
prednisone. Nine had a partial or complete remission, and all
relapsed upon discontinuing prednisone. Five of the 9 patients
were subsequently treated with cyclophosphamide; 3 achieved
a remission, and the other 2 had no response. Of the 23 patients,
6 have shown signs of progressive renal failure; in 4 who
underwent a second renal biopsy, focal and segmental sclerosis
was detected. No treatment was given to the 6 patients with
isolated hematuria. At followup they continued to have hema-
tuna, and none of them showed signs of renal failure.
In summary, about one-half of patients with proteinuric 1gM
mesangial nephropathy responded to steroid therapy, whether
or not proteinuria was accompanied by hematuria. Approxi-
mately one-third showed evidence of progressive renal failure,
and the finding of focal sclerosis can be anticipated in these
patients' renal biopsies if renal biopsy is repeated. In contrast,
patients without proteinuria who had isolated hematuria and
mesangial 1gM nephropathy had a benign and stable course.
The clinical outcome, as assessed by response to prednisone or
cyclophosphamide and development of renal failure or focal
sclerosis, did not correlate with the degree of mesangial prolif-
eration or with the presence or absence of electron-dense
deposits in the original renal biopsy. It is clear that the features
that distinguish 1gM mesangial nephropathy from other entities
can be observed only by immunohistologic methods. The light
and electron microscopic picture of 1gM mesangial nephropathy
is, in some patients, identical to that of minimal-change disease.
The reason for emphasizing this point is that, if only light and
electron microscopy are performed, 1gM mesangial nephrop-
athy can be misdiagnosed as minimal-change disease. The only
distinction between these entities is the immunofluorescence
picture of 1gM and C3 deposits in the mesangium. It is impor-
tant not to confuse these two disorders; 1gM mesangial nephro-
pathy is a form of mesangial proliferative glomerulonephritis,
an entity with a pathogenesis different from that of minimal-
change disease. It is therefore not surprising that the outcome
and response to therapy of these two disorders is different, with
minimal-change disease having a far more favorable prognosis.
Is 1gM mesangial nephropathy a separate entity?
Since the description of 1gM mesangial nephropathy in 1978,
several papers have supported the original finding that 1gM
mesangial nephropathy is clinically distinct. Other authors have
taken the opposing view, that 1gM mesangial nephropathy is
part of the clinical spectrum of minimal-change disease or, to
put it another way, that the finding of 1gM and C3 mesangial
deposits in a patient with "minimal-change disease" does not
change the diagnosis or prognosis. Issues in the diagnosis and
treatment of glomerulonephritis are seldom clear-cut, and ex-
perts often express different views. This is understandable if
one considers that the distinction between these entities is
based on defining what is minimal change by light microscopy
and what is negative by immunofluorescence, both of which can
be highly subjective. For example, some authors call small
amounts of 1gM deposits negligible or negative, whereas others
report the same finding as being positive. Furthermore, it is
sometimes forgotten that glomerular disorders are defined by
both the pathologic picture and the clinical course, particularly
the response to therapy. Thus disorders that may have similar
microscopic findings can only be distinguished in their natural
history by careful clinical followup. To arrive at a consensus
concerning the status of 1gM mesangial nephropathy, it should
be sufficient to review the papers in question and come to a
conclusion. This can be done but is complicated by the different
terms used in describing biopsy findings and by the lack of
standardization of treatment regimens, particularly the use of
different definitions of steroid-sensitive, dependent, and resis-
tant. In 1983, Tejani and Nicastri reviewed their own patients
and compared them with patients in the literature [801. All
patients reviewed had 1gM mesangial deposits with varying
degrees of mesangial changes by light microscopy. Considering
all the patients in the various published series, 20% to 50% had
persistent proteinuria despite treatment with high-dose ste-
roids. Of the 25% to 50% who did respond to steroid treatment,
the majority later became resistant to continued administration
of the drug. Many of the patients who became steroid depen-
dent or resistant were given a trial of cyclophosphamide or
chlorambucil. In 40% to 80% of patients treated with cytotoxic
therapy, proteinuria did not improve. Finally 33% to 100% of
patients in the various series progressed from mesangial prolif-
erative glomerulonephritis to focal sclerosis, as documented by
a second renal biopsy.
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Table 3. Comparison of the results of steroid treatment between
papers affirming and those denying that 1gM mesangial nephropathy is
distinct from minimal-change disease
Percentage response to steroids
Sensitive Dependent Resistant
Affirmative papersa
mean 36 36 28
range 0—68 0—67 0—52
Denial papersb
mean 44 27 28
range 30—55 25—30 18—40
Adapted from Refs. 6, 80—87.
b Adapted from Refs. 88—91.
To provide a current perspective on 1gM mesangial nephrop-
athy, I have combined the information in the 1983 review [80]
with that in 12 other papers that contain adequate clinical
information to permit analysis and comparison of patient groups
[6, 81—91]. I arbitrarily used the response to steroid treatment as
the basis by which to compare the various patient groups (Table
3). I defined steroid sensitive as a complete remission of
proteinuria (less than 200 mg/24 hours) occurring with the initial
steroid treatment. Steroid dependent means that a relapse of
proteinuria occurred upon tapering or discontinuation of the
drug. Finally, steroid resistant indicates that proteinuria per-
sisted despite drug therapy. Nine of the 13 papers concluded
that 1gM mesangial nephropathy is clinically distinct from
minimal-change disease [6, 80—871, whereas 4 concluded that
the two conditions are clinically indistinguishable [88—91]. In
the papers reporting 1gM mesangial nephropathy as a separate
entity, 0% to 68% of the patients were steroid sensitive, 0% to
67% were steroid dependent, and 0% to 52% were steroid
resistant. In the 4 papers in which 1gM mesangial nephropathy
was thought not to be distinct from minimal-change disease,
30% to 55% of patients were steroid sensitive, 25% to 30% were
steroid dependent, and 18% to 40% were steroid resistant.
The steroid responsiveness of all the 13 reports differs
dramatically from the 95% response rate reported earlier from
large studies of minimal-change disease in children [56, 61] and
adults [62]. The original distinctions between 1gM mesangial
nephropathy and minimal-change disease were (1) the presence
of 1gM deposits within the mesangium, and (2) a poor response
rate to steroid therapy. If one accepts that 1gM deposits can
exist in minimal-change disease, and if one is willing to accept
that only 30% to 55% of patients with minimal-change disease
are responsive to a course of steroids, then obviously the two
disorders are indistinguishable. This is the position taken by the
authors of the 4 papers concluding that the disorders are
similar. I think this viewpoint is incompatible with the pub-
lished data on the natural history of minimal-change disease.
Thus, the burden of proof is on the authors of these 4 papers to
explain why their patients with 1gM mesangial deposits and
alleged "minimal-change disease" did so poorly when treated
with steroids.
If 1gM mesangial deposits are indicative of a less-favorable
prognosis, is the poor prognosis due to the 1gM deposits or to
the often-associated mesangial proliferation, or to both? Sepa-
rating these two variables in the published reports is difficult.
Given that patients with 1gM deposits have mesangial prolifer-
ation, the results of large studies of pediatric patients would
suggest that these patients would have a less-favorable re-
sponse to steroids. These studies have shown a higher propor-
tion of steroid nonresponders among patients with mild or
diffuse mesangial proliferation [92, 93]. Unfortunately, in these
reports immunofluorescent studies are not included or not
emphasized, so direct comparison of the data with those from
patients considered to have 1gM mesangial nephropathy is
difficult. Most nephrologists would concur that the presence of
1gM deposits in the setting of diffuse mesangial proliferation is
associated with a worse prognosis than is that associated with
minimal-change disease. But what about patients who have 1gM
deposits but only minimal changes by light microscopy? Iden-
tifying the response to therapy and outcome in this group of
patients from the literature is difficult. I believe that the first
patient presented today was such a case and that the 1gM
deposits did predict a poor response to steroid therapy.
Reports by Tejani and coworkers compared two groups of
nephrotic patients, both of whom had minimal changes by light
microscopy but in whom 1gM was present in one and not the
other [80, 94]. Their analysis indicated that the patients with
1gM deposits were significantly older at the onset of the
nephrotic syndrome. Sixty percent of patients with 1gM depos-
its were steroid dependent compared with only 14% without
1gM deposits. When treated with cyclophosphamide, 100% of
the patients without 1gM deposits had a remission, whereas
only 46% of those with 1gM deposits did so. From the compar-
ison of these two groups of patients, the authors concluded that
"since a large number of patients with the nephrotic syndrome
and mesangial 1gM deposits respond only partially to therapy, it
would appear that separation of this entity from minimal change
is imperative so that a more favorable prognosis can be given to
those whose disease is truly minimal" [80]. This is the same
conclusion that we reached in our original description of 1gM
mesangial nephropathy in 1978 [6].
Conclusions
Recent research on the anatomy, function, and biology of the
mesangium has provided a new perspective on this important
component of the glomerulus. It is now appreciated that the
mesangial uptake of macromolecules is secondary to significant
plasma flow that occurs through the mesangial matrix, and that
this flow likely contributes to the glomerular filtration rate.
Mesangial cells, through their contractile property and respon-
siveness to angiotensin II, are major determinants of glomerular
hemodynamics. The discovery that mesangial cells can be
stimulated to transform into cells resembling monocytes or
macrophages has important pathophysiologic significance. Such
transformation might explain why immunologic or other stimuli
can injure glomeruli by stimulating the mesangium to start a
cycle of perpetual cell proliferation and matrix expansion that
can lead to sclerosis. Understanding the potential of the mesan-
gium to convert from a resting to a stimulated state provides an
insight into the pathogenesis of mesangial proliferative glomer-
ulonephritis and how this disorder can be confused with both
minimal-change disease and idiopathic focal sclerosis [95, 96].
The separation of these disorders into three separate entities is
supported by experimental evidence about the pathogenesis of
each disorder. Similar support is derived from analysis of the
response of patients with the different disorders to steroid and
cytotoxic drug therapy as well as from the ultimate outcome in
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terms of progressive renal failure. Continued application of the
techniques of biochemistry and cell biology to the study of the
mesangium will likely yield important new insights.
Questions and answers
DR. STEPHEN KORBET (Assistant Professor of Medicine,
Rush Medical College, Chicago, Illinois): I am curious about
your data in which response to prednisone therapy is used to
differentiate between patients with minimal-change disease who
have 1gM deposits in the mesangium and those who do not. You
note that 90% of patients without 1gM deposits respond to
therapy within 8 weeks, whereas those with deposits do not
respond as well. This does appear to be the case for children.
The majority of your patients with 1gM deposits, however, were
adults. Other data suggest that adults with minimal-change
lesions do not respond to prednisone therapy as quickly as
children do [97, 98]. Therefore, I wonder whether the poor
response to prednisone that you report in patients with, versus
those without, 1gM deposits might not in fact be the result of an
inadequate course of therapy in your adult patients.
DR. BORDER: You raise a good point. I am not convinced that
adults do respond less well than children, but it is possible. The
children included in our study had a poor response to predni-
sone treatment; the response was similar to that which we
observed in the adults. Longer treatment in both groups might
have produced a more favorable outcome but almost certainly
at the expense of increased side effects. I am not convinced that
adults do respond less well, but I think that it is a point worthy
of study.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital, Chicago): If minimal-change disease
is the consequence of circulating material that is injurious to the
epithelial cell, why does the disease respond so well to steroids?
DR. BORDER: The immediate and simple answer to your
question is that no one knows how steroids work in the
treatment of proteinuric disorders. The usual reply is that
steroids are anti-inflammatory and that this action is beneficial
in immunologically mediated glomerulonephritis; there is only
indirect evidence, however, that this is how steroids work in
this condition. In fact, recent evidence from cell biology indi-
cates that glucocorticoids can mimic growth factors and stimu-
late cellular production of collagen and fibronectin—compo-
nents of the extracellular matrix. This effect, especially in
minimal-change disease, may neutralize the influence of the
"soluble toxin" and restore glomerular epithelial metabolism to
normal with restoration of the GBM and podocytes and with
termination of proteinuria. Steroids also might act at the level of
the extracellular matrix and modify the response to growth
factors like interleukin- 1.
DR. SERAFINO GARELLA (Associate Chairman, Department
of Medicine, Michael Reese Hospital): You said that mesangial
cells are of two main types, those that are intrinsic to the
mesangium, and those that are derived from the bone marrow.
Is there any information regarding which cell type is involved in
causing mesangial damage in response to a variety of stimuli?
DR. BORDER: No good quantitative data are available about
the contribution of both cells to mesangial proliferation and
sclerosis. The data! presented about interleukin-l being 3 times
higher in immune-complex-treated mesangial cells probably
represented intrinsic contractile mesangial cells that were pro-
ducing interleukin- 1. The description of the transformation
from the monocyte into the macrophage-active immune effec-
tive cell is for the extrinsic cell. But we do not have a good
understanding of the interrelationships between these two cells
in terms of disease progression and their contribution to matrix
production and sclerosis.
DR. MELVIN SCHWARTZ (Professor of Pathology, Rush Med-
ical College): I want to point out several morphologic observa-
tions that raise problems with the postulate that minimal-change
disease progresses through mesangial proliferative glomerulo-
nephritis to focal sclerosis. My observations in adult patients
with focal sclerosis suggest that mesangial 1gM deposits and
mesangial proliferation are not invariably seen in association
with focal sclerosis at the time of biopsy [99]. If it were a
significant factor in the progression of the disease, it would be
seen much more commonly. This objection does not even
consider to what extent and how diffusely 1gM deposits must be
found to be considered significant. The second problem, as you
have mentioned, is that there is not a good animal model for
focal sclerosis. However, we have examined renal biopsies
from patients who had progressive focal segmental glomerulo-
sclerosis in their native kidneys and who developed nephrotic
syndrome very early in their posttransplant course [100]. This
comes quite close to being an experimental model because we
can date precisely the onset of the disease as the time of the
transplant operation. These patients developed massive pro-
teinuria within one month of transplantation and did not show
mesangial proliferation or large deposits of 1gM. Interestingly,
one of these patients, who excreted 20 g of protein per day 4
weeks after transplantation, did not have diffuse foot-process
fusion, but the foot-process fusion that was present was seen in
association with ultrastructural evidence of glomerular epithe-
hal-cell injury. Because these early biopsies did not have focal
sclerosis and the mesangial pathology was unimpressive, the
initial biopsies were consistent with minimal-change disease.
When histologic evidence of glomerular pathology appeared on
subsequent biopsies, it consisted of focal-segmental evidence of
glomerular epithelial-cell injury. In a large series of adult
patients biopsied early in the clinical course of focal sclerosis,
mesangial injury is not the predominent histologic lesion;
rather, isolated epithelial-cell lesions appear to be the earliest
histologic sign of focal glomerular sclerosis [101]. So I wish to
insert a note of caution by saying that it seems unwise to place
the primary emphasis on mesangial injury when morphologic
evidence clearly suggests that both the recurrent as well as the
early lesions involve the glomerular epithelial cells.
DR. BORDER: I would like to make it clear that I believe
minimal-change disease is a separate disorder from focal scle-
rosis and that it does not evolve into a lesion—via mesangial
proliferation—that mimics focal sclerosis. I would agree with
you that focal sclerosis is a separate entity and that the initial
lesion is in the visceral epithelial cell and not in the mesangium.
If there is a substance that is toxic to the visceral epithelial cell,
then that toxicity could be manifest by simultaneously stimu-
lating the mesangium as a secondary process so that there
develops a combination of segmental sclerosis and mesangial
proliferation. I think that if you continue to stimulate the
mesangium, segmental sclerosis does develop, but that is dif-
ferent from the pathogenesis of the focal sclerosis that you have
described.
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I believe that answers to these questions will come from
study of glomerular cell cultures and the molecular biology of
extracellular matrix. This is the right direction for research in
glomerulonephritis to be heading at this point.
DR. EDMUND LEWIS (Director, Section of Nephrology, Rush-
Presbyterian-St. Luke's Medical Center, Chicago, Illinois): Much
of the controversy surrounding the question of whether there is
an independent entity that can be characterized as "1gM
nephropathy" centers around the studies you cited that failed to
find significant correlations among the immunopathologic find-
ings, the clinical course, and the presence of mesangial hyper-
cellularity. Have you an explanation for this lack of corrobora-
tion by these investigators?
DR. BORDER: The answer to your question is complicated but
is at the heart of my presentation. I have emphasized that a
glomerular disorder is a clinicopathologic entity that is defined
by its clinical and histologic features, natural history, and
response to therapy. In my view, minimal-change disease is an
entity that has a greater than 95% likelihood of responding to
steroids and that it rarely leads to progressive renal failure, In
1978 we coined the term "1gM mesangial nephropathy" to
describe a group of patients who appeared to have "minimal
changes" but who had a poor response to steroids or to
cytotoxic drugs; moreover, some of these patients showed
evidence of progressive renal failure. What distinguished this
group of patients from those with the high rate of steroid
responsiveness and no renal failure was the presence of 1gM
deposits in the mesangium. As summarized in Table 3, 9 other
reports have supported our findings. Four reports have con-
cluded that minimal-change disease and 1gM nephropathy are
not different; the one major discrepancy, as emphasized in the
table, is that the patients with minimal-change disease in these
reports did not uniformly respond to treatment. If one accepts
this degree of resistence to steroid therapy as part of the clinical
spectrum in minimal-change disease, then indeed the distinction
between the two entities is blurred. Thus, the answer to your
question is: it depends on how you define the two entities.
DR. COHEN: You seem to be making the point that, at the
moment, the best diagnostic criterion we have of minimal-
change disease is its responsiveness to steroids. If so, wouldn't
the best strategy be to treat patients who have idiopathic
nephrotic syndrome with steroids before biopsy? Only if they
were nonresponsive or if they relapsed would one be forced to
consider other diagnostic entities that might require elucidation
by biopsy.
DR. BORDER: I don't want to equivocate. I think adults with
nephrotic syndrome should be biopsied. I think that a pediatri-
cian with a mate patient under 8 years of age with a 95% chance
of having minimal-change disease can be treated without a
biopsy. But as a nephrologist who sees and counsels patients, I
think it is important to know what the histology is so that the
patient can be accurately informed about the diagnosis and
prognosis. I think that if patients are to be treated, they should
know whether 1gM is present or not and what that might mean
in terms of outcome and response to steroids as well as about
possible progression to renal failure and/or sclerosis. I find that
specific information is helpful not only to me but also is helpful
in reassuring the patient. So, I think it is important to biopsy
patients and to know exactly what the entity is that you are
dealing with.
DR. COHEN: That depends, of course, on how risky you think
it is to administer the course of steroids required to treat
minimal-change disease effectively. If, as some people believe,
that risk is quite small, then the therapeutic strategy I suggested
would merely postpone obtaining a prognosis for a month or
two until response to treatment were known. What would one
lose by such an approach?
DR. BORDER: I think it is important to point out that often,
when one considers whether or not to do a renal biopsy, it is
assumed that one is dealing only with minimal-change disease,
focal sclerosis, or membranous nephropathy. But in reality
when we see nephrotic patients, there is a much larger number
of disorders that might be present. In the study carried out by
Dr. Arthur Cohen at UCLA, the results showed that the
pre-biopsy diagnosis made by the nephrologist was often incor-
rect [102]. Knowing the correct diagnosis also significantly
changed the recommended treatment.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief New
England Medical Center, Boston, Massachusetts): I object to
citing such studies as evidence favoring the routine use of renal
biopsy. The critical issue to be addressed in considering the
value of a biopsy is the outcome of the patient, not the opinion
of potentially biased nephrologists. Indeed, when patient out-
come is the only metric, the strategy of "blind" steroid therapy
as outlined here by Dr. Jordan Cohen is just as efficacious as the
biopsy-first strategy [103]. In addition, we have no evidence
that biopsy-derived prognostic information produces a net
benefit for the patient.
DR. BORDER: I admire Dr. Kassirer and his colleagues for
having produced an elegant computer model of the decision to
perform a renal biopsy. Unfortunately, I don't believe in it. I
wish that I could, but the model seems to me to be contrived
and detached from reality in much the way computer models of
the stock market fail to predict which stock to buy. One obvious
problem with the model is that it emphasizes response to
therapy in terms of proteinuria rather than the prognosis for
renal function. I believe patients should be told if they have a
high risk of developing renal failure (as with focal sclerosis) or
that the risk is quite small (as with minimal-change disease).
Furthermore, in my experience, postponing a renal biopsy often
means that it is never done.
DR. KA5SIRER: Our decision-analysis model of nephrotic
syndrome is complex only because the clinical course of this
disorder is complex. In my view, any criticism that our model is
contrived must be accompanied by specific references to how
and where it departs from reality. Your only specific criticism is
unfounded. Our model encompasses not only the effect of
therapy on proteinuria, but also the effect of treatment, non-
treatment, and biopsy-directed treatment on the development
of renal failure. In fact, the prognosis for renal function is
modeled extensively: as a function of the probability of even-
tual renal failure, the time interval before renal failure develops,
the life expectancy after renal failure develops, and the quality
of patients' lives in both time intervals.
It appears that there has been a subtle shift in the proposed
rationale for routine biopsy in nephrotic syndrome. Whereas
biopsy formerly was touted as a guide to therapy, now it is
being recommended, as you propose, as an invaluable prognos-
tic guide for the patient. But is this information worth the cost
and risk of biopsy? Is the biopsy-derived prognosis invariably
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correct? Isn't nearly comparable information attained by the
response to steroid therapy? The point I made earlier is that
these questions also should be subjected to rigorous study
before we shift our view that routine biopsy should be per-
formed for its prognostic value alone.
All models, including those embodied in computer programs,
should be analyzed meticulously for deviations from the real
world. So far, both the structure of the decision in our explicit
model and the data we employed have withstood the test of
extensive public scrutiny.
DR. KM LAU (Director, Division of Nephrology, Michael
Reese Hospital): I was intrigued by the soluble-toxin hypothe-
sis for the pathogenesis of minimal-change disease. In that
context, would you care to comment on two other forms of
presentation of this disease, one in association with nonsteroi-
dal agents and the other in association with Hodgkin's disease?
Why don't we see minimal-change disease more often in those
conditions if a soluble toxin is involved? For example, why
doesn't every patient taking nonsteroidal agents develop ne-
phrotic syndrome?
DR. BORDER: Non-steroidal drugs can produce minimal-
change disease where the only finding is effacement of the
podocytes. I don't know whether it is caused by the direct effect
of the drug. The finding of minimal-change disease in Hodgkin's
disease is of great interest, but there is no direct information
about the nature of the "toxin." Minimal-change disease also
has been described secondary to other types of tumors.
DR. JAMES BOURDEAU (Staff Nephrolo gist, Michael Reese
Hospital): You pointed out that patients with 1gM mesangial
glomerulopathy have a very much lower response rate to
prednisone than do those with minimal-change disease. Are
there any circumstances under which you would not recom-
mend at least a trial of prednisone in patients with 1gM
mesangial glomerulopathy?
DR. BORDER: Yes, if patients are asymptomatic, there is no
reason to treat them with steroids. Also, if another disorder
were present, such as active infection, one might withhold
steroid therapy.
DR. BOURDEAU: Are there any special signs or indications
that would persuade you not to give at least a trial of steroids to
a patient who has idiopathic nephrotic syndrome?
DR. BORDER: If the patient were not symptomatic and the
nephrotic syndrome were only mild, I would not advocate
therapy. On the other hand, I would not withhold treatment if
the patient insisted on it.
DR. COHEN: How do you fit secondary focal sclerosis into
your current scheme of thinking?
DR. BORDER: I think focal sclerosis represents simply the
continued stimulation of the mesangium by immune-complex
deposition or by growth factors. This stimulation results in
accumulation of some kind of altered extracellular matrix that
has either been produced in excess or is not being removed. I
alluded to this earlier. One can see sclerosis in vitro as
described in studies done by Sterzel and colleagues [38]. Aging
mesangial cells produce a matrix-like material that forms nod-
ules that resemble sclerosis in glomeruli. This is the best
explanation that we have at this point. I think that the mesan-
gium is very critical to the process of sclerosis.
DR. ROGER RODBY (Assistant Professor of Medicine, Rush
Medical College): Have any of your patients with 1gM mesan-
gial nephropathy who developed renal failure received renal
transplants? If so, has the original disease recurred in any of the
allografts?
DR. BORDER: None of the patients have gone on to develop
end-stage renal disease. Most of what I called renal failure was
in patients with creatinines in the 2.5—4.0mg/dl range. Whether
these patients will develop end-stage renal disease has not been
established in our study. Other studies indicate that some
patients can progress to end-stage renal disease [80]. There is
one case report of 1gM mesangial nephropathy recurring in the
transplanted kidney and producing nephrotic syndrome, much
as focal sclerosis does [82].
DR. COHEN: Do the bone-marrow-derived cells found in the
mesangium reside there permanently, or are they migratory
cells?
DR. BORDER: It is hard to obtain precise kinetics but it seems
that they do migrate. The nice work that Schreiner and Unanue
have done using irradiation shows that there is a constant
trafficking of cells from the bone marrow into the mesangium
[43].
DR. COHEN: Does that raise the possibility that these cells
might bring something injurious to the mesangium as a result of
their migration from elsewhere in the body?
DR. BORDER: I suspect that it is possible, but we have no
information about it.
DR. GARELLA: A substantial body of work indicates that
increased glomerular permeability and proteinuria follow the
injection of certain soluble substances, more specifically, pos-
itively charged molecules that permeate the glomerular base-
ment membrane. These cationic molecules seem to reduce the
negative electrical charge of the glycoprotein that coats the
epithelial cells' foot processes and cause their flattening out.
You now suggest that conditions that have a primary effect on
the mesangium might be responsible for proteinuria, even
though the mesangium is not in direct contact with the epithelial
cell. What is the pathophysiologic process that links the mesan-
gial injury with the alteration in the electrical charge on the
outside of the glomerular basement membrane and its morpho-
logic manifestation, the fusion of the foot processes?
DR. BORDER: It is likely that the epithelial and mesangial cells
work synergistically to produce and maintain the glomerular
basement membrane and mesangial extracellular matrix. Injury
to one or both cells may alter the properties of the glomerular
wall, including loss of the anionic sites, which can lead to
proteinuria.
DR. COHEN: Along those same lines, is there any evidence
that the mesangial cell is responsible for the synthesis of
glomerular basement membrane?
DR. BORDER: That is unclear. The mesangial extracellular
matrix is GBM-like in that it contains similar components such
as laminin, fibronectin, and collagen. The presence of a mesan-
gial channel for ultrafiltration suggests that the selectivity
properties of the mesangium are similar to those of the GBM.
DR. KASSIRER: I find the classification of the disorders you
have been discussing rather confusing; the question before us is
how to define 1gM nephropathy. Should the entity be defined as
Tejani has done, namely, one that consists of the combination
of idiopathic nephrotic syndrome, minimal changes on biopsy,
and 1gM on immunofluorescence microscopy, or should the
definition include the response to therapy, as you have pro-
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posed? My overwhelming preference is to follow Tejani's
classification, and define a reproducible, recognizable clinico-
pathologic entity. The advantage of this approach is that all
other aspects of a given disease entity—namely, the predispos-
ing causes, prognosis, associations with other diseases, and
therapeutic responses—can all be assessed using a standard
definition of the disease. A similar clinicopathologic classifica-
tion has worked effectively as "new" clinical disorders have
been dissected away from others. Idiopathic IgA nephropathy
is a good example. Would you respond to my concern?
DR. BORDER: Before the development of modern renal im-
munopathology, pathologists attempted to classify glomerular
disorders according to their appearance by light microscopy.
This was unsuccessful because lesions that appear alike can
have an entirely different pathogenesis. An example is crescen-
tic glomerulonephritis, a pathologic entity that can be caused by
anti-GBM antibodies, immune complexes, or possibly by sen-
sitized lymphocytes alone. A different pathogenetic mechanism
implies a different therapeutic approach and prognosis. Figure 7
makes the same point for minimal-change disease, focal sclero-
sis, and 1gM mesangial nephropathy: they all can look alike by
light microscopy. Dr. Kassirer, to use your own example, IgA
nephropathy was only separated from other forms of mesangial
proliferative glomerulonephritis by the use of immunofluores-
cence microscopy. This development is similar to the discovery
that 1gM deposits indicate a disorder different from minimal-
change disease. The difference in response to therapy is further
support for this view, The combination of descriptive, patho-
genetic, and therapeutic information may bring real meaning
and clinical utility to the classification of glomerular diseases.
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